Does the IL6 rs1800795 GG variant increase IL-6 pathway responsiveness and CRP production?

The IL6 rs1800795 GG variant and the hepatic JAK-STAT3 pathway form a direct genetic and molecular axis that regulates systemic inflammatory tone.

Genetic mechanisms of IL-6 responsiveness

• Promoter transcriptional activity: The rs1800795 GG genotype (representing the ancestral -174G allele) acts as a functional high-expressing variant. While the C allele alters repressive transcription factor binding sites for NF-1 and Smad4 to downregulate transcription, the GG genotype sustains higher baseline and stimulated promoter activity.
• Pathway transduction: This elevated expression increases circulating IL-6 ligand availability, indirectly enhancing downstream gp130-mediated signaling (though some fibroblast models display an exceptional CC-driven elevation).

Hepatic CRP synthesis and low-grade inflammation

• JAK-STAT3 signaling: Circulating IL-6 binds to the IL-6Rα/gp130 receptor complex, activating JAK to phosphorylate and dimerize STAT3.
• Epigenetic promoter activation: Phosphorylated STAT3 translocates to the nucleus, binding directly to proximal CRP promoter response elements at positions -72, -108, -134, and -164. STAT3 also acts as an epigenetic pioneer factor, driving localized CpG demethylation of the CRP promoter and recruiting cooperative transcription factors like C/EBPβ and NF-κB.
• Systemic inflammatory tone: During chronic, low-grade inflammation, persistent, modest elevations of IL-6 continuously stimulate this hepatic axis, maintaining high-sensitivity CRP (hsCRP) levels in the range of 2–10 mg/L.

Bottom line

• The IL6 rs1800795 GG variant increases IL-6 ligand availability, driving downstream hepatic JAK-STAT3 signaling and CRP promoter demethylation to maintain elevated baseline hsCRP levels (2–10 mg/L) during chronic, low-grade inflammation.